Cargando…

Comparison of different vasodilators, endothelin antagonist, PDE5 inhibitior and sGC stimulators, in an animal model of secondary pulmonary hypertension: effects on “desaturation”

Detalles Bibliográficos
Autores principales:	Becker, Eva Maria, Stasch, Johannes-Peter, Bechem, Martin, Truebel, Hubert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363245/ http://dx.doi.org/10.1186/1471-2210-11-S1-P5

Ejemplares similares

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension
por: Becker, Eva Maria, et al.
Publicado: (2013)

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
por: Becker-Pelster, Eva M., et al.
Publicado: (2022)

sGC redox regulation and asthma
por: Stuehr, Dennis J, et al.
Publicado: (2015)

Structural insights into sGC activation by different activators
por: van den Akker, Focco, et al.
Publicado: (2011)

Beyond Vasodilator: Anti-Apoptotic Effect of Endothelin Receptor Antagonist
por: Chang, Sung-A
Publicado: (2014)

Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis
por: Sandner, Peter, et al.
Publicado: (2015)

sGC activators and stimulators attenuate ischemia/reperfusion injury of the lung
por: Egemnazarov, Bakytbek, et al.
Publicado: (2009)

sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension
por: Vogel, Julia, et al.
Publicado: (2021)

Structural insights into sGC
por: Akker, Focco van den, et al.
Publicado: (2009)

Phenotypes of sGC mutant mice in basic conditions, disease and shock
por: Brouckaert, Peter, et al.
Publicado: (2009)

Molecular aspects of sGC regulation
por: Marletta, Michael A, et al.
Publicado: (2011)

Targeting native and apo-sGC
por: Struthers, Mary, et al.
Publicado: (2013)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272
por: Becker, Eva Maria, et al.
Publicado: (2001)

Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension
por: Jones, Emma S, et al.
Publicado: (2009)

New clinical results with sGC stimulators
por: Behr, Jürgen
Publicado: (2011)

Synthesis and evaluation of bifunctional sGC regulators
por: Chrominski, Mikolaj, et al.
Publicado: (2013)

Conformational changes involved in sGC activation
por: Marletta, Michael A, et al.
Publicado: (2013)

The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure
por: Haase, N, et al.
Publicado: (2015)

Increases survival by apo-sGC activation via post-stroke blood brain barrier stabilisation and anti-inflammation
por: Langhauser, Friedericke, et al.
Publicado: (2013)

Lack of correlation between sGC subunit expression and sGC activity in cerebral development is due to non-heterodimerizing subunits in vivo
por: Haase, Nadine, et al.
Publicado: (2009)

A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-Inflammatory Activities of Nitric Oxide
por: Wittmann, Christine, et al.
Publicado: (2015)

Synergistic mutations in soluble guanylyl cyclase (sGC) reveal a key role for interfacial regions in the sGC activation mechanism
por: Childers, Kenneth C., et al.
Publicado: (2019)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

A molecular view of the regulation of sGC activity
por: Marletta, Michael A, et al.
Publicado: (2009)

Genetic modifiers of hypertension in sGC-deficient mice
por: Buys, Emmanuel
Publicado: (2013)

The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015)

New vitamin B(12) derivatives activates sGC
por: Gryko, Dorota, et al.
Publicado: (2011)

Gemfibrozil as a potential heme-independent sGC activator
por: Sobolevsky, Michael, et al.
Publicado: (2011)

Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil could salvage ED-patients with insufficient response to PDE5 inhibitors after cavernous nerve injury
por: Oudot, Alexandra, et al.
Publicado: (2011)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Inhaled nitric oxide: an sGC-dependent IOP lowering agent
por: Lieb, Wolfgang S, et al.
Publicado: (2015)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation
por: Saffaran, Sina, et al.
Publicado: (2018)

Genetic silencing of sGC β1 in cancer: role of epigenetic regulation
por: Sotolongo, Alex, et al.
Publicado: (2013)

Is Innervation of the Neuromuscular Junction at the Diaphragm Modulated by sGC/cGMP Signaling?
por: Lukáčová, Nadežda, et al.
Publicado: (2020)

sGC Activity and Regulation of Blood Flow in a Zebrafish Model System
por: Vishnolia, Krishan K., et al.
Publicado: (2021)

Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO
por: de la Fuente-Alonso, Andrea, et al.
Publicado: (2021)

sGC Stimulation Saves the Diabetic Heart: Red Blood Cells to the Rescue
por: Papapetropoulos, Andreas, et al.
Publicado: (2023)

Non-endothelial endothelin counteracts hypoxic vasodilation in porcine large coronary arteries
por: Hedegaard, Elise R, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_eimhtlund2jlt8q93kimc9pgtp